Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review). Du J, Shen H, Zeng T, Liu W, et al. Int J Oncol 2026;68:28.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Du J, Shen H, Zeng T, Liu W, et al. Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review). Int J Oncol 2026;68:28.
PMID: 41456439